Research
Hormonal
Met72 allele carriers, particularly women, exhibit a lower prevalence of hypertension compared to non-carriers, suggesting a protective effect against cardiovascular comorbidities associated with obesity.
For obese women with the Met72 variant, there is an observed lower risk of hypertension. This does not replace blood pressure monitoring, but it suggests that genetic factors play a role in cardiovascular health independent of BMI. Regular monitoring is still essential.
ModerateSupportsMEDIUM confidence
SOS Met72(+) obese women had a lower (11.4%; p<0.032) prevalence of hypertension than noncarriers (23.9%).
Why this rating
The finding is statistically significant but based on self-reported data and a specific subgroup (obese women in SOS study).
Source
Role of Ghrelin Polymorphisms in Obesity Based on Three Different Studies
Olavi Ukkola et al. · Obesity Research · 2002
DOI 10.1038/oby.2002.106
cohort · n=3004Cited 184×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Carriers of the preproghrelin Leu72Met polymorphism (specifically Met72 allele) exhibit lower body mass index, fat mass, and visceral adiposity compared to non-carriers, suggesting a protective effect against obesity.Moderate
- The Arg51Gln mutation in the ghrelin gene is associated with significantly lower plasma ghrelin concentrations, but this reduction does not translate to a protective effect against obesity or altered obesity-related phenotypes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →